Nevertheless, although anti-CD19 CAR-T cell therapy showed the most prominent clinical outcome in B-ALL, it was demonstrated that the tumor cells could escape this immunotherapeutic approach. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.